Uromedica Announces Launch of ProACT™ Adjustable Continence Therapy for Men with FDA Approval and Reimbursement Coding
July 11, 2017
First patients enrolled in French Randomized Trial Between Uromedica’s Adjustable Continence Therapy (ACT) and Boston Scientific’s AMS 800 Artificial Urinary Sphincter (AUS)
July 4, 2016
New ProACT Paper in Urology: Maximum Urethral Closure Pressure Increases After Successful Adjustable Continence Therapy (ProACT) for Stress Urinary Incontinence After Radical Prostatectomy
April 26, 2016
ProACT Adjustable Continence Therapy for Men PMA Approved by USA Food and Drug Administration (FDA)
November 24, 2015.